Related Experiment Video
Updated: Nov 9, 2025

Measuring Cardiac Autonomic Nervous System ANS Activity in Children
Published on: April 29, 2013
Characteristics of Danish children registered with and pharmacologically treated for hypertension
Adam Femerling Langhoff1, Malene Landbo Børresen, Malgorzata Pulczynska Wason
1adam.femerling.langhoff@regionh.dk.
Insights
Pediatric hypertension diagnosis and treatment are crucial. This study highlights the importance of evaluating target-organ damage in all hypertensive children, especially those with secondary hypertension, to guide treatment and reduce long-term risks.
Area of Science:
- Pediatric Nephrology
- Pediatric Cardiology
- Clinical Medicine
Background:
- Previous studies indicate a low prevalence of hypertension in Danish children (0.04%), with over half receiving pharmacological treatment.
- This study focuses on pharmacologically treated pediatric hypertension cases at the initiation of antihypertensive therapy.
Purpose of the Study:
- To describe pharmacologically treated pediatric hypertension cases at the onset of antihypertensive therapy.
- To assess the evaluation of target-organ damage in these children and identify areas for improvement.
Main Methods:
- A retrospective review of medical records for children under 16 diagnosed with hypertension and treated with antihypertensive medicine in Central and Eastern Denmark (April 2014 - May 2015).
- Analysis of the cohort's demographic data, etiology of hypertension, and extent of target-organ damage evaluation (echocardiography, retinal examination, proteinuria).
Main Results:
- The cohort comprised 119 children, with 61% boys. The majority (80%) had secondary hypertension, predominantly of renal etiology (52%).
- Target-organ damage evaluations were performed in 77% (echocardiography), 74% (retinal exam), and 100% (proteinuria).
- Abnormalities were detected in 39% (echocardiography), 16% (retinal exam), and 66% (proteinuria) in renal etiology cases, and 30%, 24%, and 35% respectively in others. Notably, examinations were less frequent in renal etiology cases.
Conclusions:
- Target-organ damage evaluation was less comprehensive in hypertensive children with renal etiology compared to other causes.
- Comprehensive evaluation for target-organ damage is recommended for all hypertensive children to inform treatment decisions and mitigate long-term morbidity.
Introduction:
A previous study found that 0.04% of Danish children were registered with hypertension, among whom 54% were treated pharmacologically. Our study describes pharmacologically treated cases at the onset of antihypertensive therapy, noting whether the evaluation of target-organ damage could be improved.
Methods:
Our review of the medical records of children under 16 years living in Central and Eastern Denmark from April 2014 to May 2015 found that 119 children were registered with an International Classification of Diseases, tenth edition diagnosis of hypertension and treated with antihypertensive medicine.
Results:
The cohort consisted of 61% boys and 39% girls (p = 0.01). The majority of patients (80%) had secondary hypertension. Renal aetiology was found in 52%. Echocardiography, retinal examination and examination for proteinuria were undertaken in 77%, 74% and 100%, respectively. Both echocardiography and retinal examination were undertaken in 61% of patients with renal aetiology. Among the remaining patients, 95% and 89% underwent these examinations, respectively (p less than 0.001 and p less than 0.001). Abnormal echocardiography, abnormal retinal examination and proteinuria were found in 39%, 16% and 66%, respectively, of patients with renal aetiology and in 30%, 24% and 35% of the remaining patients (p = 0.3, p = 0.4 and p less than 0.001).
Conclusions:
Examination for target-organ damage was performed less often in patients with hypertension of renal aetiology than in the remaining patients. Examination for target-organ damage is recommended in all hypertensive children to determine whether treatment is indicated to reduce long-term morbidity.
Funding:
The study received funding from the Novo Nordisk Foundation, grant number NNF15OC0015702 and from Amager-Hvidovre Hospital Foundation.
Trial Registration:
not relevant.
More Related Videos
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Hypertension I: Introduction

